WO2023144793 - POL THETA INHIBITORS
National phase entry is expected:
Publication Number
WO/2023/144793
Publication Date
03.08.2023
International Application No.
PCT/IB2023/050798
International Filing Date
30.01.2023
Title **
[English]
POL THETA INHIBITORS
[French]
INHIBITEURS DE POL THÊTA
Applicants **
RHIZEN PHARMACEUTICALS AG
INCOZEN THERAPEUTICS PVT. LTD.
Inventors
VAKKALANKA, Swaroop Kumar Venkata Satya
BHUNIYA, Debnath
ELESWARAPU, Venkata Satyanarayana
Priority Data
202241005153
31.01.2022
IN
202241006844
09.02.2022
IN
202241007579
12.02.2022
IN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 4539 | |
| EPO | Filing, Examination, Granting | 29537 | |
| Japan | Filing, Examination, Granting | 3081 | |
| South Korea | Filing, Examination, Granting | 4023 | |
| USA | Filing, Examination, Granting | 17090 |
Total:
58,270
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present invention relates to compounds of formula (I), that possess DNA polymerase theta (POLQ) enzyme inhibitory activity, methods for their preparation, pharmaceutical compositions containing them, and their use in the treatment or prevention of diseases or disorders involving DNA polymerase theta (POLQ) enzyme.[French]
La présente invention concerne des composés représentés par la formule (I), qui possèdent une activité inhibitrice de l'enzyme ADN polymérase thêta (POLQ), des procédés pour leur préparation, des compositions pharmaceutiques les contenant, et leur utilisation dans le traitement ou la prévention de maladies ou de troubles impliquant l'enzyme ADN polymérase thêta (POLQ).